Lee Jonghun J, Kim Peter T W, Fischer Sandra, Fung Scott, Gallinger Steven, McGilvray Ian, Moulton Carol-Anne, Wei Alice C, Greig Paul D, Cleary Sean P
Department of Surgery, 10EN216 Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.
Ann Surg Oncol. 2014 Aug;21(8):2708-16. doi: 10.1245/s10434-014-3609-6. Epub 2014 May 8.
Hepatitis B (HBV) and hepatitis C (HCV) are well-recognized risk factors for hepatocellular carcinoma (HCC). The characteristics and clinical outcomes of HCC arising from these conditions may differ. This study was conducted to compare the outcomes of HCC associated with HBV and HCV after liver resection.
Of 386 liver resections for HCC performed between July 1992 and April 2011, 181 patients had HBV and 74 patients had HCV. Patients with HBV/HCV coinfections (n = 20), non-HBV/HCV etiology (n = 94), and postoperative death within 3 months (n = 17) were excluded. Patient, tumor characteristics, and perioperative and oncologic outcomes were compared between patients with HBV and HCV.
The patients with HBV had better overall survival (OS) than patients with HCV (68 vs. 59 months, p = 0.03); however, there was no difference in recurrence-free survival (RFS) between the groups (44 vs. 45 months, p = 0.1). The factors predictive of OS based on multivariate analyses included: vascular invasion [p < 0.01, hazard ratio (HR) = 3.4], Child-Pugh Score (p < 0.01, HR = 4.8), and underlying liver disease (HCV vs HBV) (p = 0.01, HR = 1.9). Vascular invasion and tumor number (p < 0.01, HR = 2.3 and p < 0.01, HR = 2.1) were independent predictors of RFS.
OS but not RFS after liver resection for HCC is better in patients with HBV than HCV. This survival advantage for HBV patients may be due to differences in tumor biology and outcomes after disease recurrence.
乙型肝炎(HBV)和丙型肝炎(HCV)是肝细胞癌(HCC)公认的危险因素。由这些情况引发的HCC的特征和临床结局可能有所不同。本研究旨在比较肝切除术后HBV和HCV相关HCC的结局。
在1992年7月至2011年4月期间进行的386例HCC肝切除术中,181例患者为HBV感染,74例患者为HCV感染。排除HBV/HCV合并感染患者(n = 20)、非HBV/HCV病因患者(n = 94)以及术后3个月内死亡患者(n = 17)。比较HBV和HCV患者的患者、肿瘤特征以及围手术期和肿瘤学结局。
HBV患者的总生存期(OS)优于HCV患者(68个月对59个月,p = 0.03);然而,两组之间的无复发生存期(RFS)无差异(44个月对45个月,p = 0.1)。基于多因素分析预测OS的因素包括:血管侵犯[p < 0.01,风险比(HR)= 3.4]、Child-Pugh评分(p < 0.01,HR = 4.8)以及潜在肝病(HCV与HBV)(p = 0.01,HR = 1.9)。血管侵犯和肿瘤数量(p < 0.01,HR = 2.3和p < 0.01,HR = 2.1)是RFS的独立预测因素。
HCC肝切除术后,HBV患者的OS较好,而RFS与HCV患者无差异。HBV患者的这种生存优势可能归因于肿瘤生物学和疾病复发后的结局差异。